[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,520,297
  • Shares Outstanding, K 107,357
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ 45 M
  • EBITDA $ 42 M
  • 60-Month Beta 0.36
  • Price/Sales 6.56
  • Price/Cash Flow 51.53
  • Price/Book 7.55

Options Overview Details

View History
  • Implied Volatility 47.85% (+0.14%)
  • Historical Volatility 67.78%
  • IV Percentile 15%
  • IV Rank 10.90%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 10) 1.28 (2.47%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 1,873
  • Volume Avg (30-Day) 551
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 28,270
  • Open Int (30-Day) 34,065
  • Expected Range 50.33 to 52.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 3
  • High Estimate $-0.03
  • Low Estimate $-0.07
  • Prior Year $0.29
  • Growth Rate Est. (year over year) -117.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.36 +27.85%
on 04/07/26
52.50 -1.71%
on 05/04/26
+9.11 (+21.44%)
since 04/02/26
3-Month
28.66 +80.04%
on 02/19/26
52.50 -1.71%
on 05/04/26
+11.47 (+28.58%)
since 02/04/26
52-Week
28.66 +80.04%
on 02/19/26
91.00 -43.30%
on 10/08/25
-21.17 (-29.09%)
since 05/02/25

Most Recent Stories

More News
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

CORT : 51.60 (+0.35%)
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

CORT : 51.60 (+0.35%)
Corcept: Q1 Earnings Snapshot

Corcept: Q1 Earnings Snapshot

CORT : 51.60 (+0.35%)
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 Increase in 2026 revenue guidance to $950 – $1,050 million ...

CORT : 51.60 (+0.35%)
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001)

CORT : 51.60 (+0.35%)
Corcept's Revenue Growth Trajectory Gets Its First Test Since Competitor Setbacks

Barchart Research What to Expect from CORT Earnings CORT Generated April 29, 2026 Current Price $46.59 EPS Estimate $$-0.30 Consensus Rating Moderate Buy Average Move 3.95% Corcept's Revenue Growth Trajectory...

CORT : 51.60 (+0.35%)
Corcept Earnings: What To Look For From CORT

Corcept Earnings: What To Look For From CORT

CORT : 51.60 (+0.35%)
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference...

CORT : 51.60 (+0.35%)
Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

NEW YORK , April 21, 2026 /PRNewswire/ --

CORT : 51.60 (+0.35%)
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorliâ„¢ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 51.60 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 55.02
2nd Resistance Point 53.76
1st Resistance Point 52.68
Last Price 51.60
1st Support Level 50.34
2nd Support Level 49.08
3rd Support Level 48.00

See More

52-Week High 91.00
Fibonacci 61.8% 67.19
Fibonacci 50% 59.83
Fibonacci 38.2% 52.47
Last Price 51.60
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.